Addressing unmet medical needs in disorders of the complement and coagulation systems

Harnessing the catalytic power of proteases

Protease engineering platform – Late-stage asset in Phase 3, robust complement portfolio, clinical-stage hemophilia assets, and differentiated protease medicines

The Protease Medicines Company

Learn more about our Pipeline

SQ Marzeptacog alfa (FVlla) “MarzAA”
Hemophilia A or B w Inhibitors – ToB
Phase 3
SQ Marzeptacog alfa (FVlla) “MarzAA”
FVIID/Glanzmann/Hemlibra – ToB
Phase 1/2
IVT CB 2782-PEG
C3 degrader for Dry AMD
Preclinical
SQ CB 4332
Enhanced CFI
Preclinical
C4b Degrader
 
Preclinical
Additional Programs
 
Preclinical
SQ Dalcinonacog alfa (FIX) “DalcA”
Hemophilia B
Phase 2
CB 2679d-GT
Hemophilia B FIX Gene Therapy
Preclinical

Protease Engineering Platform

 

Late-Stage Asset

SQ Marzeptacog alfa (activated)
MarzAA (FVIIa)

Phase 3

 

Complement

CB 2782-PEG

IVT Anti-C3 Dry AMD

CB 4332 SQ Enhanced CFI

SQ Systemic Complement Degraders

Hemostasis

SQ MarzAA (FVIIa)

SQ Dalcinonacog alfa – DalcA (FIX)

Factor IX Gene Therapy

Factor Xa

The Catalyst Advantage

Drug candidates for severe medical conditions

Learn more about the medicines we are developing

See our pipeline

Addressing diseases with unmet medical needs

Share our passion about treating disease

See our publications 

Experienced and passionate team

Learn more about the Catalyst team and mission/culture

Meet the team